Clinical Trial Finder

Inclusion criteria:

• - Participant ≥ 18 year.

• - ECOG PS of 0 to 1.

• - Provision of 'archival' tumor specimen.

• - At least one measurable lesion according to RECIST v1.1, - Minimum life expectancy of 12 weeks.

• - Adequate and stable cardiac function.

• - Adequate bone marrow, liver and kidney function.

• - Body weight ≥ 35 kg.

• - Capable of giving signed informed consent.

Module 1 specific

inclusion criteria:

• Participants with locally advanced or metastatic select solid tumors (MM, Squamous cell carcinoma of skin, MCC, NSCLC, Head and neck squamous cell carcinoma, Gastric cancer/gastroesophaegeal junction cancer, RCC, HGSOC, Triple negative breast cancer) who have received adequate SoC.Module 2 specific

inclusion criteria:

• - Participants with Stage IV NSCLC Dose Escalation/Backfills.

1. Have received at least one prior regimen in metastatic setting (2L+ NSCLC). Participants with actionable tumor alterations should have received targeted therapy if locally available OR. 2. Have not received systemic therapy (1L NSCLC) and have PD-L1 expression ≥ 1%. Dose Expansion. 1. Have not received systemic therapy (1L NSCLC) and have PD-L1 expression ≥ 1%.

Exclusion criteria:

• - Any evidence of: Severe or uncontrolled systemic diseases including respiratory, cardiac or tumor-related conditions.

• - History or planned organ or allogeneic stem cell transplantation.

• - Active or prior documented autoimmune or inflammatory disorders, within the past 3 years.

• - Any prior toxicities that led to permanent discontinuation of prior immunotherapy.

• - Persistent toxicities (CTCAE Grade ≥ 2) caused by previous anti-cancer therapy.

• - Brain metastases unless treated, asymptomatic, stable, and not requiring continuous corticosteroids.

• - Acute untreated or symptomatic malignant spinal cord compression, or a history of leptomeningeal carcinomatosis.

• - Active uncontrolled or chronic infection of hepatitis B, hepatitis C.

• - Prior history of Grade ≥ 3 non-infectious pneumonitis.

• - Participant requires chronic immunosuppressive therapy (including steroids > 10 mg prednisone/day or equivalent).

• - Receipt of live attenuated vaccine within 30 days.

Module 2 specific

exclusion criteria:

• - Previous treatment with anti-TIGIT therapy.

- 1L NSCLC participants with genetic alteration such as EGFR that has a targeted therapy in 1L as per local SoC

A Phase I/II Open-label Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD6750, a CD8 Guided IL-2 Agent Alone and in Combination With Other Anti-cancer Agents in Participants with Select Advanced or Metastatic Solid Tumors

Arms

Experimental: Module 1

AZD6750 administered intravenously (IV) as a single agent

Experimental: Module 2

AZD6750 given in combination with rilvegostomig (IV)

Interventions

Drug: - AZD6750

AZD6750- CD8 guided IL-2

Drug: - rilvegostomig

Rilvegostomig- PD1-TIGIT bispecific antibody